Gsk Share Discussion Threads

[garycook] 23/6/2023 07:20

Should be way up on the Open today !

[spoole5] 23/6/2023 07:13

Settlement reached to stop the california trial next month. Well that's set a precedent.

[spoole5] 22/6/2023 12:31

Down more than AZN on the back of good news.

[alphorn] 22/6/2023 10:00

GSK have their own drug delivery expertise.

[tradermichael] 22/6/2023 09:55

Acquisition target for GSK?

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing that work on the company's Oral Vaccine Programme collaboration is now set to move into a new phase.

Taking place over three years, the EncOVac Consortium is funded to develop a Phase I clinical trial ready oral vaccine candidate.

Skillington says "as technologies develop, we move away from injectables so we see great significant commercial opportunities in having an oral alternative."

The focus of the next phase is to commence the validation of the encapsulation process.

[tuftymatt] 22/6/2023 08:22

Wider market forces dragging most down right now.

On a good day yesterday / today I think we would be closer to 1400 than 1350.

[spoole5] 22/6/2023 08:04

Never known a share fall so much on good news.

[tuftymatt] 21/6/2023 08:03

Good news but what a shame it's lost on a day when inflation is the key talking / driving point.

[abdullla] 21/6/2023 08:03

Down means news not good

[tradermichael] 21/6/2023 07:51

GSK on Wednesday said that Phase 3 trial results for its Arexvy respiratory syncytial virus vaccine for older adults showed positive data.

The London-listed pharmaceutical major said results from the ongoing AReSVi-006 trial showed one dose of the vaccine was effective against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions.

Safety and reactogenicity data were consistent with initial results from the Phase 3 program, it said. The company will continue its clinical development program to evaluate longer-term follow up and optimal timing for revaccination, it said.

The group said the data will be submitted to the U.S. Food and Drug Administration and other regulators for review.

[pierre oreilly] 20/6/2023 16:14

Yes, you started several months ago.

[abdullla] 20/6/2023 16:09

Heading down hill

[cumnor] 16/6/2023 21:38

UK pension funds and IIs see Walmsley as something of a dead duck with little or no vision or authority. Thus the lack of buying-despite the fact they are flush with cash-this side of the Atlantic, and this enables hedgies the other side play with the share price, like today. Until somebody with substance (AZN's ceo for eg) who is respected by the market takes over, this great company will be ignored. She has had 5 years to make her mark but the share price speaks volumes about how mgmt is viewed. imo

[abdullla] 16/6/2023 16:13

What a disgraceful performance

[lovewinshatelosses] 16/6/2023 16:08

Very good, anhar. Recommended your post :)

[tradermichael] 16/6/2023 11:05

LOL .....;0)

[anhar] 16/6/2023 09:41

Great stuff TM, I've made a small fortune from following broker advice. Unfortunately I started with a large one.

[tradermichael] 15/6/2023 12:21

JP Morgan always well behind the pack.

Based on 10 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months, the average price target is 1,525.00p with a high forecast of 1,730.00p and a low forecast of 1,300.00p. The average price target represents a 11.31% change from the last price of 1,370.00p.

[alibizzle] 15/6/2023 11:55

JP Morgan given shares £1400 forecast

[tradermichael] 15/6/2023 11:13

Well, for many years it seemed that the GSK dividend was barely affordable. However, GSK has said it plans to raise the annual dividend to 56.5p per share in 2023, a target that brokers think is likely. Furthermore, analysts expect the full-year payout will increase again to 59.9p next year, far better than the healthcare sector average at 1.45%.

[anhar] 14/6/2023 12:39

I don't see much to celebrate about the divi TM - and I'm an income investor who has held GSK for decades for the divis. They have been cut substantially with the demerger so that even the combined divis from new GSK and HLN, which I've retained, are well below the old GSK payout.

[tradermichael] 14/6/2023 09:04

Still, 14p/share dividend pays out in a month's time (13 July) .....;0)